Company news: Zydus Cadila

Zydus Cadila has received tentative approval from the United States Food and Drug Administration (USFDA) for Sitagliptin tablets for sale in the US markets in strengths of 25 mg, 50 mg and 100 mg. In a filing to the exchanges, the company said the drug will be produced at the group’s formulations facility at SEZ, Ahmedabad. The group has more than 217 approvals, and has so far, filed over 330 abbreviated new drug applications. Shares of Cadila Healthcare edged down 2.89 per cent at ₹408.65 on the BSE.